Literature DB >> 34331257

Life-threatening myositis after one dose of nivolumab in a patient with nonmetastatic completely resected cutaneous melanoma.

Tomaž Rus1, Milica Gregorič Kramberger1, Gregor Brecl Jakob1, Lea Leonardis2, Marija Meznaric3.   

Abstract

Entities:  

Keywords:  Adjuvant therapy; Adverse events; Immune checkpoint inhibitors; Nivolumab-induced myositis; Nonmetastatic melanoma

Year:  2021        PMID： 34331257     DOI： 10.1007/s13760-021-01760-9

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  6 in total

1.  Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.

Authors:  Shigeaki Suzuki; Nobuhisa Ishikawa; Fumie Konoeda; Nobuhiko Seki; Satoshi Fukushima; Kikuko Takahashi; Hisashi Uhara; Yoshikazu Hasegawa; Shinichiro Inomata; Yasushi Otani; Kenji Yokota; Takashi Hirose; Ryo Tanaka; Norihiro Suzuki; Makoto Matsui
Journal:  Neurology       Date:  2017-08-18       Impact factor: 9.910

2.  Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.

Authors:  Divyanshu Dubey; William S David; Anthony A Amato; Kerry L Reynolds; Nathan F Clement; Donald F Chute; Justine V Cohen; Donald P Lawrence; Meghan J Mooradian; Ryan J Sullivan; Amanda C Guidon
Journal:  Neurology       Date:  2019-08-12       Impact factor: 9.910

3.  Inflammatory myopathy associated with PD-1 inhibitors.

Authors:  Morinobu Seki; Akinori Uruha; Yuko Ohnuki; Sachiko Kamada; Tomoko Noda; Asako Onda; Masayuki Ohira; Aiko Isami; Sumie Hiramatsu; Makoto Hibino; Shunya Nakane; Seiya Noda; Sachiko Yutani; Akira Hanazono; Hiroshi Yaguchi; Masaki Takao; Takashi Shiina; Masahisa Katsuno; Jin Nakahara; Shiro Matsubara; Ichizo Nishino; Shigeaki Suzuki
Journal:  J Autoimmun       Date:  2019-03-10       Impact factor: 7.094

4.  Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.

Authors:  Mehdi Touat; Thierry Maisonobe; Samuel Knauss; Omar Ben Hadj Salem; Baptiste Hervier; Karine Auré; Tali-Anne Szwebel; Nora Kramkimel; Claire Lethrosne; Jean-Frédéric Bruch; Pauline Laly; Jacques Cadranel; Nicolas Weiss; Anthony Béhin; Yves Allenbach; Olivier Benveniste; Timothée Lenglet; Dimitri Psimaras; Werner Stenzel; Sarah Léonard-Louis
Journal:  Neurology       Date:  2018-08-08       Impact factor: 9.910

5.  Two cases of anaphylaxis due to contrast media during administration of nivolumab and ipilimumab in metastatic renal cell carcinoma.

Authors:  Kunihisa Nezu; Hiromichi Katayama; Atsushi Kyan
Journal:  Int Cancer Conf J       Date:  2019-09-30

6.  Myasthenic crisis and polymyositis induced by one dose of nivolumab.

Authors:  Toshihiro Kimura; Satoshi Fukushima; Azusa Miyashita; Jun Aoi; Masatoshi Jinnin; Takayuki Kosaka; Yukio Ando; Masakazu Matsukawa; Hiroyuki Inoue; Kazuma Kiyotani; Jae-Hyun Park; Yusuke Nakamura; Hironobu Ihn
Journal:  Cancer Sci       Date:  2016-07       Impact factor: 6.716
  6 in total
  1 in total

1.  Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.

Authors:  Naoki Hamada; Ayaka Maeda; Kaoru Takase-Minegishi; Yohei Kirino; Yumiko Sugiyama; Ho Namkoong; Nobuyuki Horita; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.